Loading...
•
Sep 30, 2023
TherapeuticsMD Q3 2023 Earnings Report
TherapeuticsMD transitioned into a royalty-based business and reported a net loss from continuing operations of $1.4 million for Q3 2023.
Key Takeaways
TherapeuticsMD reported Q3 2023 financial results, highlighting a net loss from continuing operations of $1.4 million, or $0.13 per share, and license and service revenues of $(0.1) million. The company is focused on cost control and is evaluating strategic alternatives.
Net loss from continuing operations was $1.4 million, or $0.13 per share.
License and service revenues were $(0.1) million.
Gross royalties totaled $1.2 million for the quarter.
Total operating expenses decreased by approximately 88.2% compared to Q3 2022.
TherapeuticsMD
TherapeuticsMD
Forward Guidance
TherapeuticsMD is evaluating strategic alternatives, including potential acquisition, merger, or sale of assets. However, there is no assurance of a transaction or its timing.